Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risedronate: clinical usage.

R D Chapurlat1, P D Delmas

  • 1Department of Rheumatology and Bone Diseases, Pavillon F, Hôpital E. Herriot, 5 Place d'Arsonval, 69437 Lyon, France.

International Journal of Clinical Practice
|June 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postmenopausal women with normal BMD who have fractures have deteriorated bone microarchitecture: A prospective analysis from The OFELY study.

Bone·2024
Same author

Klinefelter Bone Microarchitecture Evolution with Testosterone Replacement Therapy.

Calcified tissue international·2022
Same author

Cost-effectiveness of treatment of women aged 70 years and older with both osteopenia and microstructural deterioration.

Bone·2020
Same author

Muscle mass is associated with incident fracture in postmenopausal women: The OFELY study.

Bone·2016
Same author

Has sclerostin a true endocrine metabolic action complementary to osteocalcin in older men?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016
Same author

Vertebral Scheuermann's disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015

Risedronate, a bisphosphonate drug, effectively prevents bone loss and reduces fractures in postmenopausal osteoporosis and glucocorticoid-induced bone loss. It also improves symptoms and bone lesions in Paget's disease of bone.

Area of Science:

  • Pharmacology
  • Bone Biology
  • Rheumatology

Background:

  • Bisphosphonates are a class of drugs that inhibit bone resorption.
  • Increased bone resorption is implicated in conditions like postmenopausal osteoporosis, glucocorticoid-induced bone loss, and Paget's disease of bone.

Purpose of the Study:

  • To evaluate the efficacy and safety of risedronate in managing various bone resorption disorders.
  • To assess risedronate's impact on bone loss, fracture incidence, bone pain, and radiographic lesions.

Main Methods:

  • Placebo-controlled clinical trials were conducted.
  • Studies included postmenopausal women with osteoporosis, individuals on glucocorticoid therapy, and patients with Paget's disease of bone.

Main Results:

Related Experiment Videos

  • Risedronate prevented bone loss in postmenopausal women and reduced vertebral and non-vertebral fractures, including hip fractures.
  • The drug prevented bone loss in men and women receiving glucocorticoids.
  • Risedronate significantly decreased bone pain and turnover, and improved radiographic lesions in Paget's disease.

Conclusions:

  • Risedronate is a safe and well-tolerated bisphosphonate.
  • It offers a new therapeutic option for postmenopausal osteoporosis, glucocorticoid-induced bone loss, and Paget's disease of bone.